We are live on
!
Find out more
CM
CM Management Portfolio holdings
AUM
$120M
1-Year Est. Return
37.12%
This Fund
S&P 500
This Quarter
Est. Return
-5.23%
1 Year Est. Return
+37.12%
3 Year Est. Return
+141.34%
5 Year Est. Return
+139.46%
10 Year Est. Return
–
AUM
$99.5M
AUM Growth
-$12.5M
(-11%)
Cap. Flow
-$3.66M
Cap. Flow
% of AUM
-3.68%
Top 10 Holdings %
Top 10 Hldgs %
41.5%
Holding
62
New
5
Increased
25
Reduced
4
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cytokinetics
CYTK
|
+$1.84M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$1.03M |
| 3 |
Herc Holdings
HRI
|
+$852K |
| 4 |
Stanley Black & Decker
SWK
|
+$843K |
| 5 |
Warner Bros
WBD
|
+$837K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$4.08M |
| 2 |
Copa Holdings
CPA
|
+$2.64M |
| 3 |
B
Barrick Mining
B
|
+$1.94M |
| 4 |
ClearPoint Neuro
CLPT
|
+$1.79M |
| 5 |
Pan American Silver
PAAS
|
+$1.62M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 36.19% |
| 2 | Materials | 10.41% |
| 3 | Industrials | 10.18% |
| 4 | Technology | 9.3% |
| 5 | Financials | 9.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Newell Brands
NWL
$2.16B
| $310K | 0.31% |
+50,000
| New | +$401K |
|
52
BioCardia
BCDA
$12.7M
| $191K | 0.19% |
75,000
+50,000
| +200% | +$121K |
|
53
Battalion Oil
BATL
$35.9M
| $176K | 0.18% |
135,000
| – | – |
|
54
Cognition Therapeutics
CGTX
$82.3M
| $168K | 0.17% |
400,000
+200,000
| +100% | +$118K |
|
55
Compass Therapeutics
CMPX
$373M
| – | – |
-310,000
| Closed | -$450K |
|
|
56
Copa Holdings
CPA
$5.56B
| – | – |
-30,000
| Closed | -$2.64M |
|
57
CVS Health
CVS
$137B
| – | – |
-25,000
| Closed | -$1.12M |
|
58
Edesa Biotech
EDSA
$50.6M
| – | – |
-110,000
| Closed | -$185K |
|
|
B
59
Barrick Mining
B
$62.2B
| – | – |
-125,000
| Closed | -$1.94M |
|
|
60
Pan American Silver
PAAS
$18.6B
| – | – |
-80,000
| Closed | -$1.62M |
|
|
61
Royalty Pharma
RPRX
$26.1B
| – | – |
-160,000
| Closed | -$4.08M |
|
|
WBA
62
DELISTED
Walgreens Boots Alliance
WBA
| – | – |
-125,000
| Closed | -$1.17M |
|
Similar funds
CC
DG
ACM
WAG
BCWM
WF
SA
SRL
CM Management's Q1 2025 Portfolio in Review
As of Q1 2025, CM Management held 62 positions worth $99.5M, down 11% from $112M the previous quarter. Its ten largest holdings account for 41% of the portfolio.
CM Management withdrew a net $3.66M in Q1 2025, closing 8 positions and reducing 4 holdings. Its most notable exit was Royalty Pharma, an estimated $4.08M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 40% a quarter earlier, followed by Materials and Industrials.
Against the trend, CM Management opened a new position in Cytokinetics worth $1.61M.
- CM Management's largest Q1 2025 buy was Cytokinetics: 40,000 shares worth $1.61M.
- CM Management added most to Iovance Biotherapeutics in Q1 2025, an estimated $1.03M increase.
- CM Management's biggest Q1 2025 reduction was ClearPoint Neuro, cutting an estimated $1.79M.
- CM Management fully exited Royalty Pharma in Q1 2025, selling an estimated $4.08M.
- CM Management's ten largest holdings make up 41% of its $99.5M portfolio in Q1 2025.
- CM Management opened 5 new positions and closed 8 in Q1 2025.
- CM Management's portfolio value fell 11% quarter-over-quarter to $99.5M.
Based on CM Management's 13F filing for Q1 2025, filed 9 May 2025.